Jiangsu Kanion Pharmaceutical Co., Ltd (SHA: 600557), a Chinese pharmaceutical company, has announced that it has received approval from the US Food and Drug Administration (FDA) to initiate a clinical study for its pipeline candidate, KYS202004A, in the treatment of psoriasis.
KYS202004A: A Dual-Targeted Fusion Protein for Psoriasis
KYS202004A is an in-house developed dual-targeted fusion protein that is indicated for the treatment of psoriasis. Psoriasis is an immune-mediated chronic, recurrent, inflammatory, and systemic disease that is triggered by a combination of genetic and environmental factors. Clinically, the disease presents as scaly erythema or plaques, which can be localized or widely distributed across the skin.
Clinical Study Significance
The approval to conduct a clinical study in the US is a significant step for Jiangsu Kanion Pharmaceutical as it seeks to evaluate the safety and efficacy of KYS202004A in treating psoriasis. This development highlights the company’s commitment to advancing novel therapeutic options for patients suffering from this common skin condition.-Fineline Info & Tech
Leave a Reply